Altre lingue CytoMed Therapeutics Limited

Azioni

GDTC

SGXZ17669631

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
2,03 ^USD	+1,50%		-0,50%	-58,57%

24/05	CytoMed Therapeutics Limited approva le dimissioni di Wu Tao Thomas e del Dr. Lucas Luk Tien Wee come Amministratori	CI
22/04	CytoMed Therapeutics Limited riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

CytoMed Therapeutics : Board re organization Form 6 K	20/06
CytoMed Therapeutics : Annual Shareholders Meeting - Form 6-K	24/05
CytoMed Therapeutics Limited Announces Board and Audit Committee Changes	24/05
CytoMed Therapeutics : PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	24/04
CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/04
Certain Ordinary Shares of CytoMed Therapeutics Limited are subject to a Lock-Up Agreement Ending on 14-APR-2024.	14/04
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics Limited to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18/03
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Limited Announces Research Collaboration with Sengkang General Hospital Pte Ltd to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04/03
CytoMed Therapeutics Receives Patent in Malaysia for its Prospective Cancer Therapy	29/01
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29/01
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29/01
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology	05/12
CytoMed Therapeutics Limited Reports Earnings Results for the Half Year Ended June 30, 2023	17/11
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update	17/11
CytoMed Therapeutics to Present at the Benchmark Company s Upcoming Discovery One-on-One Investor Conference	15/11
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference	14/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue CytoMed Therapeutics Limited

Azioni

GDTC

SGXZ17669631

Altre lingue

Filtri